Madrigal Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 85 to 94 Monday.
This unique rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research reveals that the top-performing stocks often have an RS Rating of over 80 in the early stages of their moves.
How To Use Stock Charts To Stay Profitable And Protected
Madrigal Pharmaceuticals is now considered extended and out of buy range after clearing a 298.00 buy point in a second-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Madrigal Pharmaceuticals showed 0% earnings growth in its most recent report, while sales growth came in at 0%.
The company earns the No. 113 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
